The global Recombinant Protein Therapeutics CDMO Market is expected to reach USD 52.0 billion by 2030 and is expected to expand at a CAGR of 13.95% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing technological innovations about the development of novel recombinant protein therapeutics and rising research and development for biologics are anticipated to influence the recombinant protein therapeutics CDMO industry positively. The development of novel recombinant protein therapeutics has observed significant advancements due to various technological innovations.
Recombinant
proteins are bioengineered proteins produced by introducing the gene encoding
the desired protein into a host cell, typically a microorganism or a mammalian
cell, to express and produce the protein of interest. Several protein
engineering platform technologies are currently employed to enhance the
circulating half-life, targeting the precision and functionality of novel
therapeutic protein drugs. These technologies also aim to boost production
yield and ensure product purity.
Besides,
the biopharmaceutical industry has witnessed significant growth, with an
increasing number of companies investing in research and development of
biologics, including recombinant proteins. This growth has been facilitated by
advancements in manufacturing technologies, including adopting single-use
bioreactors and other innovative production methods. For instance, in January
2024, Eurofins CDMO Alphora, Inc. announced the successful completion of its
pilot-scale biologics development facility. With an expansive area of 3,300
square feet, this facility is exclusively dedicated to developing and scaling
monoclonal antibodies (mAbs) and other therapeutic proteins derived from
mammalian sources.
Moreover,
the global increase in the prevalence of chronic and complex diseases, such as
cancer, autoimmune disorders, & metabolic diseases, has increased the demand
for innovative and effective therapeutic options. Recombinant protein
therapeutics offer a diverse range of candidates to address these complex
medical conditions. For instance, based on estimates from the American Cancer
Society, it is projected that in 2023, there will be approximately 1,958,310
new cases of cancer and 609,820 cancer-related deaths in the U.S. Furthermore,
according to a research article published by Oxford University, in June 2022,
the number of approved and marketed antibody therapies reached 162, nearly half
of which (42.6%) were being developed for the treatment of cancer.
In
March 2023, the U.S. FDA granted accelerated clearance to Incyte Corporation's
retifanlimab-dlwr for the treatment of adult patients with metastatic or recurrent,
locally advanced Merkel Cell Carcinoma (MCC). Besides, biological therapy in
cancer supports repairing, stimulating, or enhancing the immune response.
Therefore, many pharmaceutical & biopharmaceutical companies are willing to
invest in cancer-related novel treatments. Such advancements collectively aim
to achieve a higher yield of quality products.
List of Key Players in the Recombinant Protein
Therapeutics CDMO Market
- Richter-Helm
BioLogics
- Lonza
- Catalent,
Inc
- FUJIFILM
Diosynth Biotechnologies
- WuXi
Biologics
- Curia
Global, Inc.
- Batavia
Biosciences B.V.
- HALIX B.V.
- BIOVIAN
- Enzene
Biosciences Ltd
Related Press
Release@ Recombinant
Protein Therapeutics CDMO Market Report
Recombinant Protein Therapeutics CDMO Market Report
Highlights
- The others
segment dominated the market in 2023. The segment growth is driven by
increasing recombinant protein therapies as a safer option than
plasma-derived products owing to the potential to reduce bloodborne
transmission of infectious diseases
- Based on the
source, mammalian systems held the largest market share of 67.4% in 2023
attributed to an increase in the adoption of mammalian systems for
sourcing recombinant proteins. Mammalian cell culture systems offer
advantages in producing complex proteins with appropriate
post-translational modifications, making them suitable for a wide range of
therapeutic applications
- Based on
indication, the metabolic disorders segment held a market share of 21.8%
in 2023. The segment is driven by a growing aging population, and robust
demand for pharmaceutical industry, which has contributed to its
prominence in this field
- North
America dominated the market with a share of 38.5% in 2023. The region has
a strong R&D infrastructure and a robust biopharmaceutical industry,
which has contributed to the market growth. Furthermore, the U.S. has a
sophisticated and well-developed manufacturing infrastructure for
biopharmaceuticals, including recombinant protein therapeutics
Request For A Free Consultation @ https://www.grandviewresearch.com/request-free-consultation/455567/rfc
Recombinant Protein Therapeutics CDMO Market Segmentation
Grand
View Research has segmented the global recombinant protein therapeutics CDMO
market based on type, source, indication, and region:
Recombinant Protein Therapeutics CDMO By Type Outlook
(Revenue, USD Million, 2018 - 2030)
- Growth
Hormones
- Interferons
- Vaccines
- Immunostimulating
Agents
- Others
Recombinant Protein Therapeutics CDMO By Source Outlook
(Revenue, USD Million, 2018 - 2030)
- Mammalian
Systems
- Microbial
Systems
- Others
Recombinant Protein Therapeutics CDMO By Indication
Outlook (Revenue, USD Million, 2018 - 2030)
- Oncology
- Infectious
Diseases
- Immunological
Disorders
- Metabolic
Disorders
- Haematological
Disorders
- Others
Recombinant Protein Therapeutics CDMO By Regional Outlook
(Revenue, USD Million, 2018 - 2030)
- North
America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle East
and Africa (MEA)
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment